DK1272505T3 - 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater - Google Patents

8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater

Info

Publication number: DK1272505T3
Authority: DK; Denmark
Prior art keywords: sup; 8beta; 11beta; substituted; compounds
Prior art date: 2000-04-12

Application number

DK01940331T

Other languages

English (en)

Inventor

Alexander Hillisch

Karl-Heinrich Fritzemeier

Olaf Peters

Nico Braeuer

Christa Hegele-Hartung

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-12

Publication date

2005-11-07

2000-04-12 Priority claimed from DE10019167A external-priority patent/DE10019167A1/de

2001-04-12 Application filed by Schering Ag filed Critical Schering Ag

2005-11-07 Application granted granted Critical

2005-11-07 Publication of DK1272505T3 publication Critical patent/DK1272505T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Pregnancy & Childbirth (AREA)
Toxicology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK01940331T 2000-04-12 2001-04-12 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater DK1272505T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10019167A DE10019167A1 (de)	2000-04-12	2000-04-12	Substituierte Estratriene als selektiv wirksame Estrogene
US20737000P	2000-05-26	2000-05-26

Publications (1)

Publication Number	Publication Date
DK1272505T3 true DK1272505T3 (da)	2005-11-07

Family

ID=26005365

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01940331T DK1272505T3 (da)	2000-04-12	2001-04-12	8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater
DK01931609T DK1272504T3 (da)	2000-04-12	2001-04-12	8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK01931609T DK1272504T3 (da)	2000-04-12	2001-04-12	8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener

Country Status (25)

Country	Link
US (3)	US20040029847A1 (da)
EP (2)	EP1272505B1 (da)
JP (2)	JP3828423B2 (da)
CN (1)	CN100453549C (da)
AT (2)	ATE363487T1 (da)
AU (3)	AU2001273945A1 (da)
BG (1)	BG107173A (da)
BR (1)	BR0109983A (da)
CA (1)	CA2406177C (da)
CZ (1)	CZ20023382A3 (da)
DE (1)	DE50112561D1 (da)
DK (2)	DK1272505T3 (da)
EA (1)	EA006299B1 (da)
EE (1)	EE200200589A (da)
ES (2)	ES2245694T3 (da)
HR (1)	HRP20020892B1 (da)
HU (1)	HUP0300335A2 (da)
IL (2)	IL152248A0 (da)
MX (1)	MXPA02010066A (da)
NO (2)	NO325337B1 (da)
NZ (1)	NZ543724A (da)
PL (1)	PL207488B1 (da)
PT (1)	PT1272504E (da)
SK (1)	SK14632002A3 (da)
WO (2)	WO2001077138A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK14632002A3 (sk) *	2000-04-12	2003-03-04	Schering Aktiengesellschaft	Substituované estratriény a ich použitie ako selektívne účinných estrogénov
DE10027887A1 (de)	2000-05-31	2001-12-13	Jenapharm Gmbh	Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10039199A1 (de) *	2000-08-10	2002-02-21	Schering Ag	Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
GB0020498D0 (en)	2000-08-18	2000-10-11	Sterix Ltd	Compound
DE10151363A1 (de) *	2001-10-17	2003-05-08	Schering Ag	Somatotrope Therapie
DE10226326A1 (de) *	2002-06-11	2004-01-15	Schering Ag	9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
EP1468690B1 (en) *	2003-03-27	2008-10-08	Pantarhei Bioscience B.V.	Use of estrogens for the treatment of infertility in male mammals
DE10318896A1 (de) *	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
PT1689410E (pt) *	2003-11-26	2008-08-18	Bayer Schering Pharma Ag	Prevenção e tratamento de doenças cardíacas hipertensivas pelos estrogénios selectivos 8beta-vinil-estra-1,3,5(10)-trieno-3,17beta-diol e 17beta-fluoro-9alfa-vinil-estra-1,3,5(10)-trieno-3,16alfa-diol
US7534780B2 (en)	2004-05-21	2009-05-19	Bayer Schering Pharma Aktiengesellschaft	Estradiol prodrugs
DE102005057224A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057225A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2014672A1 (en) *	2007-07-12	2009-01-14	Bayer Schering Pharma Aktiengesellschaft	8-beta-substituted estratrienes as selectively active estrogens
US20110052699A1 (en) *	2008-02-13	2011-03-03	Adrian Funke	Drug delivery system with stabilising effect
EP2249803A2 (en) *	2008-02-13	2010-11-17	Bayer Schering Pharma Aktiengesellschaft	Estradiol-containing drug delivery system
EP2143432A1 (en)	2008-07-11	2010-01-13	Bayer Schering Pharma AG	9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
JP2012509286A (ja) *	2008-11-21	2012-04-19	バイエルファーマアクチエンゲゼルシャフト	薬物送達システム
RS62297B1 (sr)	2011-11-23	2021-09-30	Therapeuticsmd Inc	Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2743E (fr) *	1902-01-11	1904-12-15	Adolphe Ernest Pointe	Panification augmentant le rendement et la digestibilité
JPS454059Y1 (da) *	1967-11-04	1970-02-25
JPS454060Y1 (da) *	1967-12-11	1970-02-25
US3501530A (en) *	1968-02-27	1970-03-17	American Cyanamid Co	Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes
US3681407A (en) *	1969-06-18	1972-08-01	American Cyanamid Co	3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof
US3806546A (en) *	1969-06-18	1974-04-23	American Cyanamid Co	Steroid-like compounds and method of synthesis
US3709878A (en) *	1970-07-20	1973-01-09	Sandoz Ag	8 alpha-methyl-substituted-steroids
US3736345A (en) *	1971-05-18	1973-05-29	American Cyanamid Co	Steroid-like compounds and method of synthesis
US4961931A (en) *	1982-07-29	1990-10-09	Alza Corporation	Method for the management of hyperplasia
DE4018828C2 (de) *	1989-06-08	1999-05-12	Schering Ag	Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren
DE69702450T2 (de) *	1996-05-01	2001-03-08	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	21-substituierte progesteron derivate als antigestagene
WO2000031112A1 (en) *	1998-11-20	2000-06-02	Akzo Nobel N.V.	Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
SK14632002A3 (sk) *	2000-04-12	2003-03-04	Schering Aktiengesellschaft	Substituované estratriény a ich použitie ako selektívne účinných estrogénov
DE10019167A1 (de) *	2000-04-12	2001-10-18	Schering Ag	Substituierte Estratriene als selektiv wirksame Estrogene
DE10318896A1 (de) *	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

2001
- 2001-04-12 SK SK1463-2002A patent/SK14632002A3/sk unknown
- 2001-04-12 AT AT01931609T patent/ATE363487T1/de active
- 2001-04-12 ES ES01940331T patent/ES2245694T3/es not_active Expired - Lifetime
- 2001-04-12 JP JP2001575608A patent/JP3828423B2/ja not_active Expired - Lifetime
- 2001-04-12 MX MXPA02010066A patent/MXPA02010066A/es active IP Right Grant
- 2001-04-12 EP EP01940331A patent/EP1272505B1/de not_active Expired - Lifetime
- 2001-04-12 IL IL15224801A patent/IL152248A0/xx active IP Right Grant
- 2001-04-12 DK DK01940331T patent/DK1272505T3/da active
- 2001-04-12 DK DK01931609T patent/DK1272504T3/da active
- 2001-04-12 NZ NZ543724A patent/NZ543724A/en unknown
- 2001-04-12 PT PT01931609T patent/PT1272504E/pt unknown
- 2001-04-12 US US10/257,287 patent/US20040029847A1/en not_active Abandoned
- 2001-04-12 AU AU2001273945A patent/AU2001273945A1/en not_active Abandoned
- 2001-04-12 BR BR0109983-3A patent/BR0109983A/pt not_active IP Right Cessation
- 2001-04-12 EE EEP200200589A patent/EE200200589A/xx unknown
- 2001-04-12 HR HR20020892A patent/HRP20020892B1/xx not_active IP Right Cessation
- 2001-04-12 PL PL358667A patent/PL207488B1/pl not_active IP Right Cessation
- 2001-04-12 US US10/257,288 patent/US7378404B2/en not_active Expired - Fee Related
- 2001-04-12 ES ES01931609T patent/ES2287127T3/es not_active Expired - Lifetime
- 2001-04-12 HU HU0300335A patent/HUP0300335A2/hu unknown
- 2001-04-12 AU AU5834101A patent/AU5834101A/xx active Pending
- 2001-04-12 CA CA2406177A patent/CA2406177C/en not_active Expired - Fee Related
- 2001-04-12 AU AU2001258341A patent/AU2001258341B2/en not_active Ceased
- 2001-04-12 AT AT01940331T patent/ATE302790T1/de not_active IP Right Cessation
- 2001-04-12 DE DE50112561T patent/DE50112561D1/de not_active Expired - Lifetime
- 2001-04-12 CZ CZ20023382A patent/CZ20023382A3/cs unknown
- 2001-04-12 EA EA200201052A patent/EA006299B1/ru not_active IP Right Cessation
- 2001-04-12 CN CNB018107745A patent/CN100453549C/zh not_active Expired - Fee Related
- 2001-04-12 WO PCT/EP2001/004289 patent/WO2001077138A1/de not_active Ceased
- 2001-04-12 WO PCT/EP2001/004290 patent/WO2001077139A1/de not_active Ceased
- 2001-04-12 EP EP01931609A patent/EP1272504B1/de not_active Expired - Lifetime
2002
- 2002-10-08 BG BG107173A patent/BG107173A/bg unknown
- 2002-10-10 IL IL152248A patent/IL152248A/en not_active IP Right Cessation
- 2002-10-11 NO NO20024908A patent/NO325337B1/no unknown
- 2002-10-11 NO NO20024907A patent/NO20024907L/no not_active Application Discontinuation
2008
- 2008-03-11 US US12/045,979 patent/US20080182829A1/en not_active Abandoned
- 2008-06-25 JP JP2008166585A patent/JP2008280355A/ja active Pending

Also Published As

Publication number	Publication date
NZ543724A (en)	2007-07-27
HUP0300335A2 (hu)	2003-07-28
EP1272505A1 (de)	2003-01-08
PT1272504E (pt)	2007-08-29
DE50112561D1 (de)	2007-07-12
BR0109983A (pt)	2003-02-25
CZ20023382A3 (cs)	2003-02-12
MXPA02010066A (es)	2003-06-04
JP3828423B2 (ja)	2006-10-04
CA2406177A1 (en)	2001-10-18
HK1057219A1 (zh)	2004-03-19
EP1272504A1 (de)	2003-01-08
NO20024908L (no)	2002-11-13
NO20024907D0 (no)	2002-10-11
IL152248A0 (en)	2003-05-29
PL358667A1 (en)	2004-08-09
NO325337B1 (no)	2008-03-31
AU2001273945A1 (en)	2001-10-23
HRP20020892B1 (en)	2011-08-31
CA2406177C (en)	2010-06-22
ATE363487T1 (de)	2007-06-15
US20030176405A1 (en)	2003-09-18
NO20024907L (no)	2002-12-05
PL207488B1 (pl)	2010-12-31
ES2245694T3 (es)	2006-01-16
EE200200589A (et)	2004-04-15
WO2001077139A1 (de)	2001-10-18
AU5834101A (en)	2001-10-23
ATE302790T1 (de)	2005-09-15
EA200201052A1 (ru)	2003-04-24
US20080182829A1 (en)	2008-07-31
EP1272504B1 (de)	2007-05-30
AU2001258341B2 (en)	2007-03-15
BG107173A (bg)	2003-05-30
DK1272504T3 (da)	2007-10-01
IL152248A (en)	2008-06-05
SK14632002A3 (sk)	2003-03-04
JP2008280355A (ja)	2008-11-20
US20040029847A1 (en)	2004-02-12
EA006299B1 (ru)	2005-10-27
WO2001077138A1 (de)	2001-10-18
JP2003530403A (ja)	2003-10-14
CN100453549C (zh)	2009-01-21
EP1272505B1 (de)	2005-08-24
ES2287127T3 (es)	2007-12-16
US7378404B2 (en)	2008-05-27
HRP20020892A2 (en)	2005-02-28
CN1433424A (zh)	2003-07-30
NO20024908D0 (no)	2002-10-11

Publication	Publication Date	Title
ATE302790T1 (de)	2005-09-15	8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate
RU97104120A (ru)	1999-04-20	Фармацевтические композиции, содержащие производные эстра-1,3,5(10)-триена
EA200100108A1 (ru)	2001-12-24	Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
ES2299730T3 (es)	2008-06-01	Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
BG105804A (en)	2002-03-29	16-hydroxyestratrienes as selective acting estrogens
ES2286042T3 (es)	2007-12-01	18-nor-esteroides como estrogenos eficaces selectivamente.
ES2300431T3 (es)	2008-06-16	Esteroides androgenos halogenados en posicion 11 y sustituidos en posicion 7.
KR101006612B1 (ko)	2011-01-10	선택적 활성 에스트로겐으로서의 9-ａｌｐｈａ-치환에스트라트리엔
HU230920B1 (hu)	2019-03-28	Depresszió kezelésére szolgáló androgén gyógyászati készítmények
YU77302A (sh)	2005-11-28	8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni
KR100200462B1 (ko)	1999-06-15	아로마타제 억제제로서 유용한 2베타, 19-메틸렌아미노 다리 걸친 스테로이드
EA201000097A1 (ru)	2010-08-30	8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
ES2260294T3 (es)	2006-11-01	17-metilen-esteroides halogenados en posicion 4, procedimientos para su preparacion y composiciones que contienen estos compuestos.
KR20080072087A (ko)	2008-08-05	Ｅｒ-베타 선택적 물질의 전구약물, 그의 제조 방법 및그것을 포함하는 제약 조성물
NZ536882A (en)	2007-07-27	9-Alpha-substituted estratrienes as selectively active estrogens